SA522432710B1 - مركبات حلقية غير متجانسة على هيئة مثبطات نازع تشبّع دلتا-5 وطرق لاستخدامها - Google Patents

مركبات حلقية غير متجانسة على هيئة مثبطات نازع تشبّع دلتا-5 وطرق لاستخدامها

Info

Publication number
SA522432710B1
SA522432710B1 SA522432710A SA522432710A SA522432710B1 SA 522432710 B1 SA522432710 B1 SA 522432710B1 SA 522432710 A SA522432710 A SA 522432710A SA 522432710 A SA522432710 A SA 522432710A SA 522432710 B1 SA522432710 B1 SA 522432710B1
Authority
SA
Saudi Arabia
Prior art keywords
compounds
delta
methods
heterocyclic compounds
desaturase inhibitors
Prior art date
Application number
SA522432710A
Other languages
Arabic (ar)
English (en)
Inventor
جينيفر ار. الين،
ميشيلا بلتراني،
ماثيو بي بوربياو،
تودورا بي. داميانوفا،
باولو فينسيتي،
لاين لينجارد،
انا اي. ميناتي،
Original Assignee
امجين انك.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by امجين انك., filed Critical امجين انك.,
Publication of SA522432710B1 publication Critical patent/SA522432710B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SA522432710A 2019-11-25 2022-05-24 مركبات حلقية غير متجانسة على هيئة مثبطات نازع تشبّع دلتا-5 وطرق لاستخدامها SA522432710B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
PCT/US2020/062020 WO2021108408A1 (en) 2019-11-25 2020-11-24 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
SA522432710B1 true SA522432710B1 (ar) 2025-05-29

Family

ID=73855555

Family Applications (1)

Application Number Title Priority Date Filing Date
SA522432710A SA522432710B1 (ar) 2019-11-25 2022-05-24 مركبات حلقية غير متجانسة على هيئة مثبطات نازع تشبّع دلتا-5 وطرق لاستخدامها

Country Status (21)

Country Link
US (3) US11512097B2 (enExample)
EP (1) EP4065223A1 (enExample)
JP (2) JP7254246B2 (enExample)
KR (2) KR20230154292A (enExample)
CN (2) CN118161500A (enExample)
AR (1) AR120556A1 (enExample)
AU (1) AU2020392087B2 (enExample)
BR (1) BR112022010054A2 (enExample)
CA (1) CA3162281A1 (enExample)
CL (2) CL2022001357A1 (enExample)
CO (1) CO2022008690A2 (enExample)
CR (1) CR20220308A (enExample)
IL (1) IL293191B2 (enExample)
JO (1) JOP20220125A1 (enExample)
MX (1) MX2022006281A (enExample)
PE (1) PE20231097A1 (enExample)
PH (1) PH12022551282A1 (enExample)
SA (1) SA522432710B1 (enExample)
TW (2) TWI867822B (enExample)
UY (1) UY38971A (enExample)
WO (1) WO2021108408A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220510B2 (en) * 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
CR20220308A (es) * 2019-11-25 2022-08-04 Amgen Inc Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
JP2026500099A (ja) 2022-11-23 2026-01-06 アムジエン・インコーポレーテツド Ｆａｄｓ－１阻害剤を使用するｆａｄｓ１媒介性の疾患又は障害の処置のための患者の選択

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
ES2058069T3 (es) 1986-04-07 1994-11-01 Kumiai Chemical Industry Co Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado.
BR9713863A (pt) 1996-12-05 2000-03-14 Amgen Inc Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
EP1220857B1 (en) 1999-10-15 2005-09-21 Neurocrine Biosciences, Inc. Gonadotropin releasing hormone receptor antagonists and their related methods of use
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
TW200401770A (en) 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US7906645B2 (en) 2004-12-24 2011-03-15 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
ATE474829T1 (de) 2005-06-27 2010-08-15 Amgen Inc Entzündungshemmende arylnitrilverbindungen
WO2007027012A1 (en) 2005-07-18 2007-03-08 Samsung Electronics Co., Ltd. Video coding method and apparatus for reducing mismatch between encoder and decoder
CN101227819A (zh) 2005-07-27 2008-07-23 巴斯福股份公司 杀真菌剂5-甲基-6-苯基三唑并嘧啶基胺
MX2008001059A (es) 2005-07-27 2008-03-19 Basf Ag Fungicidas de 6-fenil-pirazolopirimidina-7-ilamina.
US20080200480A1 (en) 2005-07-27 2008-08-21 Basf Aktiengesellschaft Fungicidal 6-Phenyltriazolopyrimidinylamines
CN101360499B (zh) 2005-10-06 2015-10-07 默沙东公司 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
EP2074127A1 (en) 2006-09-28 2009-07-01 Novartis AG Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use
KR20090057416A (ko) 2006-10-05 2009-06-05 씨브이 쎄러퓨틱스, 인코포레이티드 스테아로일 ＣｏＡ 탈포화효소 억제제로서 사용하기 위한, 바이시클릭 질소 함유 헤테로시클릭 화합물
US8173661B2 (en) 2006-11-08 2012-05-08 The Rockefeller University Alpha-IIB-beta-3 inhibitors and uses thereof
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008087182A2 (de) 2007-01-19 2008-07-24 Basf Se Fungizide mischungen aus 1-methylpyrazol-4-ylcarbonsäureaniliden und azolopyrimidinylaminen
EP2131658A2 (en) 2007-01-30 2009-12-16 Basf Se Method for improving plant health
US8461077B2 (en) 2007-03-23 2013-06-11 Basf Se Combinations of active substances
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009124259A1 (en) 2008-04-04 2009-10-08 Cv Therapeutics, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US20100099561A1 (en) 2008-10-15 2010-04-22 E.I. Du Pont De Nemours And Company Heterobicyclic alkylthio-bridged isoxazolines
WO2010087467A1 (en) 2009-01-27 2010-08-05 Takeda Pharmaceutical Company Limited Delta-5-desaturase inhibitors
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2012011592A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 複素環化合物およびその用途
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8952012B2 (en) 2012-05-24 2015-02-10 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
US9505767B2 (en) 2013-09-05 2016-11-29 Genentech, Inc. Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
JP6442485B2 (ja) 2014-04-23 2018-12-19 田辺三菱製薬株式会社 新規二環性または三環性複素環化合物
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
JP2017091808A (ja) 2015-11-10 2017-05-25 株式会社フジクラ 酸化物超電導線材の製造方法及び超電導コイルの製造方法
WO2017112678A1 (en) 2015-12-21 2017-06-29 Rima Mcleod Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
SG11201901747VA (en) 2016-08-31 2019-03-28 Agios Pharmaceuticals Inc Inhibitors of cellular metabolic processes
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CN106749271B (zh) * 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
SG11201910197SA (en) 2017-05-15 2019-11-28 Dana Farber Cancer Inst Inc Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2020002869A (es) 2017-09-15 2020-07-24 Aduro Biotech Inc Compuestos de pirazolopirimidinona y usos de los mismos.
CR20220308A (es) * 2019-11-25 2022-08-04 Amgen Inc Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso

Also Published As

Publication number Publication date
CR20220308A (es) 2022-08-04
JP7698676B2 (ja) 2025-06-25
CL2022001357A1 (es) 2023-03-10
MX2022006281A (es) 2022-06-08
UY38971A (es) 2021-06-30
US12448396B2 (en) 2025-10-21
TWI815061B (zh) 2023-09-11
PE20231097A1 (es) 2023-07-18
AU2020392087A1 (en) 2022-06-09
CN114728167B (zh) 2024-03-19
TW202132317A (zh) 2021-09-01
CN114728167A (zh) 2022-07-08
JP2023078418A (ja) 2023-06-06
PH12022551282A1 (en) 2023-11-29
CO2022008690A2 (es) 2022-06-30
CL2023002486A1 (es) 2024-01-12
KR102598203B1 (ko) 2023-11-03
WO2021108408A1 (en) 2021-06-03
CN118161500A (zh) 2024-06-11
TW202409042A (zh) 2024-03-01
US11512097B2 (en) 2022-11-29
JP7254246B2 (ja) 2023-04-07
AR120556A1 (es) 2022-02-23
JOP20220125A1 (ar) 2023-01-30
KR20220106159A (ko) 2022-07-28
IL293191B2 (en) 2025-09-01
JP2022549739A (ja) 2022-11-28
KR20230154292A (ko) 2023-11-07
US20230159560A1 (en) 2023-05-25
US20210221824A1 (en) 2021-07-22
EP4065223A1 (en) 2022-10-05
IL293191A (en) 2022-07-01
BR112022010054A2 (pt) 2022-08-16
CA3162281A1 (en) 2021-06-03
AU2020392087B2 (en) 2025-10-23
TWI867822B (zh) 2024-12-21
US20210188874A1 (en) 2021-06-24
IL293191B1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
SA522432710B1 (ar) مركبات حلقية غير متجانسة على هيئة مثبطات نازع تشبّع دلتا-5 وطرق لاستخدامها
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
JOP20230138A1 (ar) مثبطات prmt5
ZA202310378B (en) Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
PH12020551464A1 (en) Cd73 inhibitors
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MY196582A (en) PD-1/PD-L1 Inhibitors
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
GEP20166484B (en) Protein kinase inhibitors
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
GEP20166443B (en) Heterocyclic compound and use thereof
MY152271A (en) Novel compounds that are erk inhibitors
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
GEP20115304B (en) PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
MX2024013215A (es) Compuestos para inhibir kif18a
UA105000C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
PH12022550130A1 (en) Enzyme inhibitors